TriSalus Life Sciences, Inc.
TLSI
$5.34
-$0.16-2.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 57.70% | 49.41% | -20.09% | -3.37% | -35.14% |
| Total Depreciation and Amortization | 7.85% | 6.87% | 67.89% | 59.42% | 119.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -111.57% | -134.44% | 514.78% | -51.72% | 14.93% |
| Change in Net Operating Assets | -1,113.16% | -1,878.21% | -25,570.83% | -219.74% | -84.17% |
| Cash from Operations | 32.32% | 19.25% | 10.86% | -65.22% | -58.08% |
| Capital Expenditure | -59.66% | 41.33% | -58.81% | -130.72% | -65.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 0.00% | 0.00% | 0.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 1,570.59% | 137.50% | 197.10% |
| Cash from Investing | 37.15% | 78.27% | 55.17% | -9.60% | -8.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -52.87% | 3.45% | 54.69% | 49.12% | 42.76% |
| Issuance of Common Stock | 288.89% | 8,622.35% | 10,930.43% | 7,206.38% | 3,848.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -81.45% | -48.99% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -108.72% | -107.26% | -107.31% | -- | -- |
| Cash from Financing | -10.69% | -30.56% | -42.17% | 186.45% | 133.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 434.82% | -232.03% | -207.53% | 219.57% | 78.17% |